Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707407 | 0.89 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9979785 | 0.86 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27809673 | 0.84 | ESR1 (0.63) | ESR1LMNACYP1A2CYP3A4MAPT | |
| SCHEMBL1960994 | 0.84 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1501802 | 0.83 | PTPN11 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15724963 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7642823 | 0.83 | HRH3 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28117969 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16259100 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL571295 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101033190-B | Method of preparing adapalene | BEIJING JHYB PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-05-04 | — | — | CN | claimed |
| CN-101033190-A | Method of preparing adapalene | BEIJING JHYB PHARMACEUTICAL TE (CN) | 2007-09-12 | — | — | CN | claimed |
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | Karyopharm Therapeutics Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3337796-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9957259-B2 | Selective HDAC1 and HDAC2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180030040-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9765066-B2 | Selective HDAC1 and HDAC2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765066-B2 | Selective HDAC1 and HDAC2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017031213-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031213-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170044144-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2017-02-16 | — | — | US | disclosed |
| US-5723666-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997048672-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5470999-A | Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity | ALLERGAN, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| US-5451605-A | Treating skin disorders | ALLERGAN, INC. (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0137010-A4 | NAPHTHYL OR TETRAHYDRONAPHTHYL-SUBSTITUTED NAPHTHOIC ACID AND DE RIVATES. | STANFORD RES INST INT (US) | 1985-08-12 | — | — | EP | disclosed |
| EP-0137010-A1 | NAPHTHYL OR TETRAHYDRONAPHTHYL-SUBSTITUTED NAPHTHOIC ACID AND DE RIVATES | SRI INTERNATIONAL (US) | 1985-04-17 | — | — | EP | disclosed |
| WO-1984003505-A1 | NAPHTHYL OR TETRAHYDRONAPHTHYL-SUBSTITUTED NAPHTHOIC ACID AND DE RIVATES | STANFORD RES INST INT (US) | 1984-09-13 | — | — | WO | disclosed |
| US-4454341-A | ANTITUMOR, SKIN DISORDERS | SRI INTERNATIONAL (US) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044144-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | HDAC1, HDAC2, HDAC11 | CA12 3911/4885CA1 3372/4885CA2 2947/4885 |
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | NAMPT, PAK3, PAK5 | CA12 4790/4885CA1 3405/4885CA2 3166/4885 |
| US-20180030040-A1 | SELECTIVE HDAC1 AND HDAC2 INHIBITORS | HDAC1, HDAC2, HDAC11 | CA12 3911/4885CA1 3372/4885CA2 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.